Simvastatin 20mg/5ml Oral Suspension ( DrugBank: Simvastatin )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 1 |
34. 神経線維腫症
臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-005742-38-GB (EUCTR) | 02/05/2013 | 05/04/2013 | Early phase triple blind placebo controlled RCT of simvastatin treatment for autism in young children with Neurofibromatosis Type 1 | Early phase triple blind placebo controlled RCT of simvastatin treatment for autism in young children with Neurofibromatosis Type 1 - SimvAstatin in Neurofibromatosis Type 1-Autism (SANTA) | Neurofibromatosis Type 1 MedDRA version: 14.1;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Trade Name: Simvastatin 20mg/5ml Oral Suspension Product Name: Simvastatin INN or Proposed INN: Simvastatin | Central Manchester University Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 0 | Phase 2 | United Kingdom |